European Commission Grants Orphan Medicinal Product Designation to Karyopharm and Menarini Group

The European Commission has granted Orphan Medicinal Product Designation to Karyopharm Therapeutics Inc., a pharmaceutical company pioneering cancer therapies, and Menarini Group, a leading international pharmaceutical company, for selinexor used to treat myelofibrosis (MF). Selinexor was granted the orphan drug designation by the US Food and Drug Administration (FDA) in May 2022. Selinexor is currently […]

Continue Reading